Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA

Decreased blood–brain barrier (BBB) efflux function of the P-glycoprotein (P-gp) transport system could facilitate the accumulation of toxic compounds in the brain, increasing the risk of neurodegenerative pathology such as Parkinson’s disease (PD). This study investigated in vivo BBB P-gp function in patients with parkinsonian neurodegenerative syndromes, using [11C]-verapamil PET in PD, PSP and MSA patients. Regional differences in distribution volume were studied using SPM with higher uptake interpreted as reduced P-gp function. Advanced PD patients and PSP patients had increased [11C]-verapamil uptake in frontal white matter regions compared to controls; while de novo PD patients showed lower uptake in midbrain and frontal regions. PSP and MSA patients had increased uptake in the basal ganglia. Decreased BBB P-gp function seems a late event in neurodegenerative disorders, and could enhance continuous neurodegeneration. Lower [11C]-verapamil uptake in midbrain and frontal regions of de novo PD patients could indicate a regional up-regulation of P-gp function.

• Publication year

  2008

• Venue

  Journal of neural transmission

• Publication date

  2008-02-12

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00702-008-0030-yPMID 18265929PMCID 2468317
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease.

  2008influential reference
• Pesticide Exposure Exacerbates α-Synucleinopathy in an A53T Transgenic Mouse Model

  2007cited by this paper
• Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model.

  2007cited by this paper
• MDR1‐P‐Glycoprotein (ABCB1) Mediates Transport of Alzheimer’s Amyloid‐β Peptides—Implications for the Mechanisms of Aβ Clearance at the Blood–Brain Barrier

  2007cited by this paper
• 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C

  2007cited by this paper
• Consistent and severe affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3

  2006cited by this paper
• Parkinson's disease dementia: what's in a Lewy body?

  2006cited by this paper
• Does the white matter matter in Alzheimer disease and cerebral amyloid angiopathy?

  2006cited by this paper
• Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt–Jakob disease

  2006influential reference
• Blood–brain barrier dysfunction in parkinsonian midbrain in vivo

  2005influential reference
• Cytoplasmic domains of the transporter associated with antigen processing and P-glycoprotein interact with subunits of the proteasome.

  2005cited by this paper
• Atypical unclassifiable parkinsonism on Guadeloupe: An environmental toxic hypothesis

  2005cited by this paper
• Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality.

  2004cited by this paper
• Potential role of ABC transporters as a detoxification system at the blood-CSF barrier.

  2004cited by this paper
• Altered P‐Glycoprotein Expression in AIDS Patients with HIV Encephalitis

  2004cited by this paper
• Inflammation and neurodegeneration in Parkinson's disease.

  2004cited by this paper
• Analysis of MDR1 haplotypes in Parkinson's disease in a white population.

  2004cited by this paper
• Accumulation of phosphorylated alpha-synuclein in aging human brain.

  2003cited by this paper
• Accumulation of Phosphorylated α‐Synuclein in Aging Human Brain

  2003cited by this paper
• Cortical and Leptomeningeal Cerebrovascular Amyloid and White Matter Pathology in Alzheimer’s Disease

  2003cited by this paper
• Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease.

  2003cited by this paper
• Cytokine Regulation of P-Glycoprotein

  2003cited by this paper
• Activated T cells modulate P-glycoprotein expression in an in vitro model of the blood-brain barrier

  2002cited by this paper
• Where Does Parkinson Disease Pathology Begin in the Brain?

  2002cited by this paper
• St Johns wort increases expression of P-glycoprotein: implications for drug interactions.

  2002cited by this paper
• An improved method for the preparation of [11C]verapamil.

  2002cited by this paper
• Cognitive impairments in advanced PD without dementia

  2002cited by this paper
• Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease.

  2002cited by this paper
• Isolation of endothelial cells from brain, lung, and kidney: expression of the multidrug resistance P-glycoprotein isoforms.

  2001cited by this paper
• Environmental toxins accelerate Parkinson’s disease onset

  2001influential reference
• P‐glycoprotein at the Blood‐Brain Barrier and Analysis of Drug Transport with Positron‐Emission Tomography

  2001cited by this paper
• Decreased platelet glutamate uptake in patients with amyotrophic lateral sclerosis

  2001cited by this paper
• beta-Amyloid efflux mediated by p-glycoprotein.

  2001cited by this paper
• Howard Henry Tooth (1856–1925)

  2000cited by this paper
• P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.

  2000cited by this paper
• Multidrug resistance transporters and modulation

  2000cited by this paper
• Pathoanatomy of Parkinson’s disease

  2000cited by this paper
• Late‐onset neurodegenerative diseases—the role of protein insolubility

  2000cited by this paper
• [Consensus on the diagnosis of multi-system atrophy].

  1999influential reference
• Graphical analysis of PET data applied to reversible and irreversible tracers.

  1999cited by this paper
• Quantification of in-vivo P-glycoprotein facilitated transport in the blood-brain barrier.

  1999cited by this paper
• Diagnostic criteria for Parkinson disease.

  1999cited by this paper
• Glial Cell Reactions in Neurodegenerative Diseases Pathophysiology and Therapeutic Interventions

  1998cited by this paper
• Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)

  1996cited by this paper
• Innervation of propatagial musculature in a flying squirrel, Glaucomys volans (Rodentia, Sciuridae).

  1996cited by this paper
• Interaction of structurally diverse pesticides with the human MDR1 gene product P-glycoprotein.

  1996cited by this paper
• White matter hyperintensities in Parkinson's disease. Clinical correlations.

  1995cited by this paper
• White Matter Hyperintensities in Parkinson's Disease: Clinical Correlations

  1995cited by this paper
• Comparing Functional (PET) Images: The Assessment of Significant Change

  1991cited by this paper
• Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

  1989cited by this paper
• Risk factors for progressive supranuclear palsy

  1988cited by this paper

• Interconnected roles of astrocytes and the blood–brain barrier in Parkinson’s disease: pathological evidence, mechanistic insights, and knowledge gaps

  2026cites this paper
• Environmental Substances Associated with Neurodegeneration: An Overview of Parkinson's Disease and Related Genotoxic Endpoints.

  2026cites this paper
• Clinical translation of nanomedicines for brain diseases: Current challenges and future directions.

  2025cites this paper
• Nanomedicine for targeting brain Neurodegeneration: Critical barriers and circadian rhythm Considerations.

  2025cites this paper
• COVID-19 Alters Inflammatory, Mitochondrial, and Protein Clearance Pathway Genes: Potential Implications for New-onset Parkinsonism in Patients

  2025cites this paper
• Causes of accumulation of excess iron in the structures of the substantia nigra of the brain in Parkinson’s disease

  2025cites this paper
• Influence of feelings on the blood-brain barrier (BBB) and drug delivery.

  2025cites this paper
• Parkinson’s disease risk factors are expressed at brain barriers

  2025cites this paper
• From blood vessels to brain cells: Connecting the circulatory system and Parkinson's disease

  2025cites this paper
• Group II metabotropic glutamate receptors modulate blood brain barrier function: direct and indirect effect through astrocytes and microglia.

  2025cites this paper
• Brainstem and cerebellar radiological findings in progressive supranuclear palsy

  2025cites this paper
• Uncovering the impact of the cardiovascular system on cerebrovascular health using MRI.

  2025cites this paper
• Ferric Ammonium Citrate Reduces Claudin-5 Abundance and Function in Primary Mouse Brain Endothelial Cells

  2025cites this paper
• Multimodal Imaging of Blood–Brain Barrier Dysfunction in Parkinson's Disease: From Pathological Mechanisms to Therapeutic Opportunities

  2025cites this paper
• Measurement of cyclosporin induced changes in P-glycoprotein function at the human blood-brain barrier using [18F]MC225 and PET

  2025cites this paper
• Restoring brain barriers: an innovative approach for treating neurological disorders

  2025cites this paper
• Electrochemical sensor involving disposable AgNW/CA fibrous membrane for levodopa quantification in body fluids

  2025cites this paper
• Modelling the innate immune system in microphysiological systems

  2024cites this paper
• Emerging Role of ABC Transporters in Glia Cells in Health and Diseases of the Central Nervous System

  2024cites this paper
• 18F-Labeled dihydropyridines via Hantzsch reaction for positron emission tomography of P-glycoprotein dysfunction.

  2024cites this paper
• Pericyte derivation and transplantation for blood-CNS barrier reconstitution in CNS disorders

  2024cites this paper
• Blood–brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy

  2024influential citation
• Advanced Noninvasive Strategies for the Brain Delivery of Therapeutic Proteins and Peptides.

  2024cites this paper
• Unlocking the Potential of Low-Molecular-Weight (Poly)phenol Metabolites: Protectors at the Blood-Brain Barrier Frontier.

  2024cites this paper
• LRRK2 G2019S Mutated iPSC-Derived Endothelial Cells Exhibit Increased α-Synuclein, Mitochondrial Impairment, and Altered Inflammatory Responses

  2024cites this paper
• Functionalized Nanomaterials Capable of Crossing the Blood–Brain Barrier

  2024cites this paper
• Curcumin as a potential therapeutic agent for treating neurodegenerative diseases.

  2024influential citation
• The Role of CSF Biomarkers in Discriminating Between Cerebral Amyloid Angiopathy and Alzheimer’s Disease Patients: Systematic Review of Clinical Studies

  2024cites this paper
• The impact of ATP-binding cassette transporters in the diseased brain: Context matters

  2024cites this paper
• Small Particles, Big Potential: Polymeric Nanoparticles for Drug Delivery in Parkinson's Disease

  2024cites this paper
• Blood-brain barrier breakdown is linked to tau pathology and neuronal injury in a differential manner according to amyloid deposition

  2023cites this paper
• Association of ABCB1 gene polymorphisms rs1128503, rs2032582, rs4148738 with anemia in patients receiving dabigatran after total knee arthroplasty

  2023cites this paper
• Quantification of P-glycoprotein function at the human blood-brain barrier using [18F]MC225 and PET

  2023cites this paper
• Microvascular blood-brain barrier alterations in isolated brain capillaries of mice over-expressing alpha-synuclein (Thy1-aSyn line 61).

  2023influential citation
• Molecular Heterogeneity of the Brain Endothelium

  2023cites this paper
• Applications and Considerations for Microfluidic Systems To Model the Blood-Brain Barrier.

  2023cites this paper
• Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women

  2023cites this paper
• Advanced radiological investigation of levodopa- induced dyskinesia in Parkinson’s disease patients: assessment of blood brain barrier function

  2022cites this paper
• WDR43 is a potential diagnostic biomarker and therapeutic target for osteoarthritis complicated with Parkinson’s disease

  2022cites this paper
• Endothelial LRP1-ICD Accelerates Cognition-Associated Alpha-Synuclein Pathology and Neurodegeneration through PARP1 Activation in a Mouse Model of Parkinson’s Disease

  2022cites this paper
• Transporter Regulation in Critical Protective Barriers: Focus on Brain and Placenta

  2022cites this paper
• The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery

  2022cites this paper
• Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis.

  2022cites this paper
• P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease

  2022cites this paper
• Implication of ABC transporters in non-proliferative diseases.

  2022cites this paper
• Systematic Review on the Role of Lobar Cerebral Microbleeds in Cognition

  2022cites this paper
• A Novel Huntington’s Disease Assessment Platform to Support Future Drug Discovery and Development

  2022cites this paper
• Microvascular Changes in Parkinson’s Disease- Focus on the Neurovascular Unit

  2022cites this paper
• Cis-p-tau plays crucial role in lysolecithin-induced demyelination and subsequent axonopathy in mouse optic chiasm.

  2022cites this paper
• Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease

  2022cites this paper
• Perfluorooctanesulfonic acid exposure altered hypothalamic metabolism and disturbed male fecundity.

  2022cites this paper
• Regulation of P-Glycoprotein in the Brain

  2022cites this paper
• Astrocytic VEGFA: An essential mediator in blood–brain‐barrier disruption in Parkinson's disease

  2021cites this paper
• Strategies to gain novel Alzheimer’s disease diagnostics and therapeutics using modulators of ABCA transporters

  2021cites this paper
• Blood–Brain Barrier and Neurodegenerative Diseases—Modeling with iPSC-Derived Brain Cells

  2021cites this paper
• First clinical assessment of [18F]MC225, a novel fluorine-18 labelled PET tracer for measuring functional P-glycoprotein at the blood–brain barrier

  2021cites this paper
• Transporter hypothesis in pharmacoresistant epilepsies. Is it at the central or peripheral level?

  2021cites this paper
• Blood-Brain Barrier Dysfunction in CNS Disorders and Putative Therapeutic Targets: An Overview

  2021cites this paper
• Altered blood–brain barrier and blood–spinal cord barrier dynamics in amyotrophic lateral sclerosis: Impact on medication efficacy and safety

  2021cites this paper
• Drug Repurposing for Alzheimer's Disease Based on Protein-Protein Interaction Network

  2021cites this paper
• Blood-brain barrier models: rationale for selection.

  2021cites this paper
• CD36 – A novel molecular target in the neurovascular unit

  2020cites this paper
• The Challenge of Modulating Heparan Sulfate Turnover by Multitarget Heparin Derivatives

  2020influential citation
• Exploring the molecular approach of COX and LOX in Alzheimer’s and Parkinson’s disorder

  2020cites this paper
• The Interplay of ABC Transporters in Aβ Translocation and Cholesterol Metabolism: Implicating Their Roles in Alzheimer’s Disease

  2020cites this paper
• Brain Endothelial P-Glycoprotein Level Is Reduced in Parkinson’s Disease via a Vitamin D Receptor-Dependent Pathway

  2020cites this paper
• PET Imaging of ABC Transporters at the Blood-Brain Barrier

  2020cites this paper
• Hypoxia, Oxidative Stress, and Inflammation: Three Faces of Neurodegenerative Diseases

  2020cites this paper
• Automated synthesis, preclinical toxicity, and radiation dosimetry of [18F]MC225 for clinical use: a tracer for measuring P-glycoprotein function at the blood-brain barrier

  2020cites this paper
• Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications

  2020cites this paper
• Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer’s disease

  2020cites this paper
• Brain Disorders and Chemical Pollutants: A Gap Junction Link? †

  2020cites this paper
• Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders.

  2020cites this paper
• Tau Protein and Its Role in Blood–Brain Barrier Dysfunction

  2020cites this paper
• Abnormal subpopulations of peripheral blood lymphocytes are involved in Parkinson's disease.

  2019cites this paper
• The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy

  2019cites this paper
• Photobiomodulation Mitigates Cerebrovascular Leakage Induced by the Parkinsonian Neurotoxin MPTP

  2019cites this paper
• Contributions of Drug Transporters to Blood-Brain Barriers.

  2019cites this paper
• Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson's disease.

  2019cites this paper
• Surface engineered liposomal delivery of therapeutics across the blood brain barrier: recent advances, challenges and opportunities

  2019cites this paper
• A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers

  2019cites this paper
• Localized Blood-Brain Barrier Opening in Ovine Model Using Image-Guided Transcranial Focused Ultrasound.

  2019cites this paper
• Preclinical Development of Novel Bifunctional Compounds for Parkinson's Disease

  2019cites this paper
• The role of mutations associated with familial neurodegenerative disorders on blood–brain barrier function in an iPSC model

  2019cites this paper
• Pre-conditioning with Remote Photobiomodulation Modulates the Brain Transcriptome and Protects Against MPTP Insult in Mice.

  2019cites this paper
• Astrocyte alterations in neurodegenerative pathologies and their modeling in human induced pluripotent stem cell platforms

  2019influential citation
• A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson’s disease, in healthy volunteers

  2019cites this paper
• Expression and Cellular Distribution of P-Glycoprotein and Breast Cancer Resistance Protein in Amyotrophic Lateral Sclerosis Patients

  2019cites this paper
• Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?

  2019cites this paper
• Advantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson's Disease.

  2019cites this paper
• Tau as a mediator of neurotoxicity associated to cerebral amyloid angiopathy

  2019influential citation
• Age-Related Functional and Expressional Changes in Efflux Pathways at the Blood-Brain Barrier

  2019cites this paper
• Profiling Brain Trauma in Professional American-style Football and the Implications to Developing Neurological Injury

  2019cites this paper
• Interleukin-4 Contributes to Degeneration of Dopamine Neurons in the Lipopolysaccharide-treated Substantia Nigra in vivo

  2018cites this paper
• A Screening Strategy for Evaluation of Drug Transport across the Blood-Brain Barrier: Application to Catechol-O-methyltransferase Inhibitors, Dopamine β-hydroxylase Inhibitors and Dibenz[b,f]azepine-5-carboxamide Derivatives

  2018cites this paper
• Intact blood‐brain barrier transport of small molecular drugs in animal models of amyloid beta and alpha‐synuclein pathology

  2018cites this paper
• Neurodegeneration and locomotor dysfunction in Drosophila scarlet mutants

  2018cites this paper
• Impaired tissue barriers as potential therapeutic targets for Parkinson’s disease and amyotrophic lateral sclerosis

  2018cites this paper
• Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?

  2018influential citation
• Imaging techniques to study drug transporter function in vivo.

  2018cites this paper